{"success":true,"data":{"pressRelease":{"id":"31184","rtpr_id":"nNFC1TtQHG","ticker":"PHIO","exchange":"NASDAQ","all_tickers":["PHIO"],"title":"Phio Pharmaceuticals Announces \"Innovations in Skin Cancer Treatment and Prevention\" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026","author":"Newsfile Corp","published_at":"2026-05-12T11:00:19.135Z","article_body":"Live virtual fireside chat — investors, advisors, and life sciences analysts\ninvited to attend\n\nFeaturing Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman\nand Force Family Office CEO Steven Saltzstein\n\nKing of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio\nPharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA\nbiopharmaceutical company developing therapeutics using its proprietary\nINTASYL(®) gene silencing technology to eliminate cancer. Phio announced\ntoday that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio\nPharmaceuticals will participate in a fireside chat with Steven Saltzstein,\nCEO, Force Family Office. Joining them will be Dr. Mary Spellman, Board\nCertified, licensed dermatologist who will explore both prevention and\nnext-generation treatment strategies for various forms of skin cancer.\n\n\"We are excited to take part in this fireside chat with Force Family Office,\"\nsaid Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. \"Dr. Spellman\nwill discuss the future direction of dermatologic oncology and highlight how\nour INTASYL® siRNA program represents a differentiated and innovative\napproach to immuno-oncology.\"\n\nDATE: Tuesday May 19, 2026\n\nTIME: 4 PM EDT\n\nREGISTRATION LINK: PHIO Pharma - Force Family Office\n(https://api.newsfilecorp.com/redirect/DOEy8fPKma)\n\nRecent Company Highlights\n\nPhio's lead clinical candidate, PH-762, is being evaluated as an intratumoral\ntherapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell\ncarcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed\ntreatment across five dose-escalation cohorts, with no dose-limiting\ntoxicities or serious adverse events. The Company has also reported a\npathological response rate in cSCC across all dosing cohorts of approximately\n65%, including an 85% pathological response (6 of 7 patients) in the\nhighest-dose cohort.\n\nPhio has indicated that FDA engagement regarding next-stage clinical\ndevelopment is targeted for the second quarter of 2026 and has reported cash\nand cash equivalents projected to sustain operations into the first half of\n2027.\n\nAbout Phio Pharmaceuticals Corp.\n\nPhio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage\nbiopharmaceutical company advancing its proprietary INTASYL(®) siRNA gene\nsilencing technology to eliminate cancer. Phio's INTASYL compounds are\ndesigned to enhance the body's immune cells to more effectively kill cancer\ncells. Phio's lead clinical development program is an INTASYL compound,\nPH-762, that silences the PD-1 gene implicated in various forms of skin\ncancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the\ntreatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell\ncarcinoma. PH-762 is a potential non-surgical treatment for skin cancers.\n\nFor additional information, visit the Company's website, www.phiopharma.com.\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements can be identified by words such as \"intends,\" \"believes,\"\n\"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggests,\" \"may,\" \"would,\"\n\"should,\" \"potential,\" \"designed to,\" \"will,\" \"ongoing,\" \"estimate,\"\n\"forecast,\" \"target,\" \"predict,\" \"could\" and similar references, although not\nall forward-looking statements contain these words. These statements, which\ninclude statements, among other things, regarding the anticipated benefits of\nour INTASYL™ RNAi platform, the results from our ongoing clinical trials,\nour expectations that our cash runway will extend into the first half of 2027,\nour expectations regarding timing of FDA submissions intended to propose and\nseek guidance for next steps in clinical study design for PH-762, our\nexpectations that such FDA submissions and any related FDA meetings will\nclarify next steps in advancing the PH-762 development program, details\nregarding our planned non-clinical toxicology study, and our ability to\nsupport ongoing clinical development, operational requirements and strategic\ninitiatives with the capital we currently have on hand, are based only on our\ncurrent beliefs, expectations and assumptions and are subject to inherent\nuncertainties, risks and changes in circumstances that are difficult to\npredict and many of which are outside of our control. Our actual results may\ndiffer materially from those indicated in the forward-looking statements as a\nresult of a number of important factors, including, but not limited to, the\nimpact of future FDA interactions on the development of our product\ncandidates; the impact to our business and operations by inflationary\npressures; recession fears; the development of our product candidates, results\nfrom our nonclinical, preclinical and clinical activities, our ability to\nexecute on business strategies, our ability to develop our product candidates\nwith collaboration partners, and the success of any such collaborations, the\ntimeline and duration for advancing our product candidates into clinical\ndevelopment, the timing or likelihood of regulatory filings and approvals, the\nsuccess of our efforts to commercialize our product candidates if approved,\nour ability to manufacture and supply our product candidates for clinical\nactivities, and for commercial use if approved, the scope of protection we are\nable to establish and maintain for intellectual property rights covering our\ntechnology platform, our ability to obtain future financing, market and other\nconditions and those risks identified in our most recent Annual Report on Form\n10-K and subsequent Quarterly Reports on Form 10-Q under the caption \"Risk\nFactors\" and in other filings the Company periodically makes with the U.S.\nSecurities and Exchange Commission. Readers are urged to review these risk\nfactors and to not act in reliance on any forward-looking statements, as\nactual results may differ from those contemplated by our forward-looking\nstatements. Phio does not undertake to update forward-looking statements to\nreflect a change in its views, events or circumstances that occur after the\ndate of this release, except as required by law.\n\nContact:\nPhio Pharmaceuticals Corp.\nJennifer Phillips: jphillips@phiopharma.com\nCorporate Affairs\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296886","article_body_html":"","raw_payload":{"data":{"id":"nNFC1TtQHG","title":"Phio Pharmaceuticals Announces \"Innovations in Skin Cancer Treatment and Prevention\" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026","author":"Newsfile Corp","ticker":"PHIO","created":"2026-05-12T11:00:19.135Z","tickers":["PHIO"],"exchange":"NASDAQ","article_body":"Live virtual fireside chat — investors, advisors, and life sciences analysts\ninvited to attend\n\nFeaturing Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman\nand Force Family Office CEO Steven Saltzstein\n\nKing of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio\nPharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA\nbiopharmaceutical company developing therapeutics using its proprietary\nINTASYL(®) gene silencing technology to eliminate cancer. Phio announced\ntoday that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio\nPharmaceuticals will participate in a fireside chat with Steven Saltzstein,\nCEO, Force Family Office. Joining them will be Dr. Mary Spellman, Board\nCertified, licensed dermatologist who will explore both prevention and\nnext-generation treatment strategies for various forms of skin cancer.\n\n\"We are excited to take part in this fireside chat with Force Family Office,\"\nsaid Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals. \"Dr. Spellman\nwill discuss the future direction of dermatologic oncology and highlight how\nour INTASYL® siRNA program represents a differentiated and innovative\napproach to immuno-oncology.\"\n\nDATE: Tuesday May 19, 2026\n\nTIME: 4 PM EDT\n\nREGISTRATION LINK: PHIO Pharma - Force Family Office\n(https://api.newsfilecorp.com/redirect/DOEy8fPKma)\n\nRecent Company Highlights\n\nPhio's lead clinical candidate, PH-762, is being evaluated as an intratumoral\ntherapy in cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell\ncarcinoma. In its Phase 1b trial, Phio has reported that 22 patients completed\ntreatment across five dose-escalation cohorts, with no dose-limiting\ntoxicities or serious adverse events. The Company has also reported a\npathological response rate in cSCC across all dosing cohorts of approximately\n65%, including an 85% pathological response (6 of 7 patients) in the\nhighest-dose cohort.\n\nPhio has indicated that FDA engagement regarding next-stage clinical\ndevelopment is targeted for the second quarter of 2026 and has reported cash\nand cash equivalents projected to sustain operations into the first half of\n2027.\n\nAbout Phio Pharmaceuticals Corp.\n\nPhio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage\nbiopharmaceutical company advancing its proprietary INTASYL(®) siRNA gene\nsilencing technology to eliminate cancer. Phio's INTASYL compounds are\ndesigned to enhance the body's immune cells to more effectively kill cancer\ncells. Phio's lead clinical development program is an INTASYL compound,\nPH-762, that silences the PD-1 gene implicated in various forms of skin\ncancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the\ntreatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell\ncarcinoma. PH-762 is a potential non-surgical treatment for skin cancers.\n\nFor additional information, visit the Company's website, www.phiopharma.com.\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Forward-looking\nstatements can be identified by words such as \"intends,\" \"believes,\"\n\"anticipates,\" \"indicates,\" \"plans,\" \"expects,\" \"suggests,\" \"may,\" \"would,\"\n\"should,\" \"potential,\" \"designed to,\" \"will,\" \"ongoing,\" \"estimate,\"\n\"forecast,\" \"target,\" \"predict,\" \"could\" and similar references, although not\nall forward-looking statements contain these words. These statements, which\ninclude statements, among other things, regarding the anticipated benefits of\nour INTASYL™ RNAi platform, the results from our ongoing clinical trials,\nour expectations that our cash runway will extend into the first half of 2027,\nour expectations regarding timing of FDA submissions intended to propose and\nseek guidance for next steps in clinical study design for PH-762, our\nexpectations that such FDA submissions and any related FDA meetings will\nclarify next steps in advancing the PH-762 development program, details\nregarding our planned non-clinical toxicology study, and our ability to\nsupport ongoing clinical development, operational requirements and strategic\ninitiatives with the capital we currently have on hand, are based only on our\ncurrent beliefs, expectations and assumptions and are subject to inherent\nuncertainties, risks and changes in circumstances that are difficult to\npredict and many of which are outside of our control. Our actual results may\ndiffer materially from those indicated in the forward-looking statements as a\nresult of a number of important factors, including, but not limited to, the\nimpact of future FDA interactions on the development of our product\ncandidates; the impact to our business and operations by inflationary\npressures; recession fears; the development of our product candidates, results\nfrom our nonclinical, preclinical and clinical activities, our ability to\nexecute on business strategies, our ability to develop our product candidates\nwith collaboration partners, and the success of any such collaborations, the\ntimeline and duration for advancing our product candidates into clinical\ndevelopment, the timing or likelihood of regulatory filings and approvals, the\nsuccess of our efforts to commercialize our product candidates if approved,\nour ability to manufacture and supply our product candidates for clinical\nactivities, and for commercial use if approved, the scope of protection we are\nable to establish and maintain for intellectual property rights covering our\ntechnology platform, our ability to obtain future financing, market and other\nconditions and those risks identified in our most recent Annual Report on Form\n10-K and subsequent Quarterly Reports on Form 10-Q under the caption \"Risk\nFactors\" and in other filings the Company periodically makes with the U.S.\nSecurities and Exchange Commission. Readers are urged to review these risk\nfactors and to not act in reliance on any forward-looking statements, as\nactual results may differ from those contemplated by our forward-looking\nstatements. Phio does not undertake to update forward-looking statements to\nreflect a change in its views, events or circumstances that occur after the\ndate of this release, except as required by law.\n\nContact:\nPhio Pharmaceuticals Corp.\nJennifer Phillips: jphillips@phiopharma.com\nCorporate Affairs\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/296886"},"type":"article","timestamp":"2026-05-12T11:00:19.192670938Z","server_sent_at_ms":1778583619192},"received_at":"2026-05-12T11:00:19.259Z","source_url":"https://www.newsfilecorp.com/release/296886"},"analysis":null,"durationMs":null,"modelName":null}}